Total Payments
$159,184
2024 Payments
$16,508
Companies
50
Transactions
611
Medicare Patients
3,140
Medicare Billing
$549,537
Payment Breakdown by Category
Other$61,870 (38.9%)
Consulting$35,545 (22.3%)
Research$32,105 (20.2%)
Travel$11,553 (7.3%)
Food & Beverage$11,340 (7.1%)
Education$6,752 (4.2%)
Gifts$19.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $35,545 | 10 | 22.3% |
| Unspecified | $32,105 | 58 | 20.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,045 | 17 | 19.5% |
| Honoraria | $29,825 | 13 | 18.7% |
| Travel and Lodging | $11,553 | 52 | 7.3% |
| Food and Beverage | $11,340 | 445 | 7.1% |
| Education | $6,752 | 14 | 4.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,000 | 1 | 0.6% |
| Gift | $19.24 | 1 | 0.0% |
Payments by Type
General
$127,079
553 transactions
Research
$32,105
58 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SK Life Science, Inc. | $38,292 | 90 | $0 (2024) |
| AQUESTIVE THERAPEUTICS, INC. | $31,433 | 16 | $0 (2022) |
| NEUROPACE, INC. | $29,883 | 71 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $20,759 | 106 | $0 (2021) |
| EISAI INC. | $16,625 | 45 | $0 (2022) |
| UCB, Inc. | $11,006 | 82 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $5,040 | 9 | $0 (2024) |
| Greenwich Biosciences, Inc. | $1,935 | 7 | $0 (2021) |
| Cyberonics, Inc. | $1,101 | 3 | $0 (2017) |
| LivaNova USA, Inc. | $372.41 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,508 | 89 | SK Life Science, Inc. ($7,464) |
| 2023 | $26,901 | 106 | SK Life Science, Inc. ($22,670) |
| 2022 | $14,343 | 79 | JAZZ PHARMACEUTICALS INC. ($4,881) |
| 2021 | $17,164 | 76 | AQUESTIVE THERAPEUTICS, INC. ($9,422) |
| 2020 | $10,624 | 27 | NEUROPACE, INC. ($6,045) |
| 2019 | $27,157 | 56 | AQUESTIVE THERAPEUTICS, INC. ($20,491) |
| 2018 | $17,881 | 65 | Sunovion Pharmaceuticals Inc. ($9,483) |
| 2017 | $28,607 | 113 | Eisai Inc. ($11,025) |
All Payment Transactions
611 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Neurology | ||||||
| 12/10/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $140.35 | General |
| Category: Neurology | ||||||
| 12/10/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $135.36 | General |
| Category: Neurology | ||||||
| 12/06/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $98.25 | General |
| 12/06/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $67.02 | General |
| 12/05/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Neurology | ||||||
| 11/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: PAIN | ||||||
| 11/19/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Neurology | ||||||
| 11/18/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $2,200.00 | General |
| Category: Neurology | ||||||
| 11/18/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Otter Pharmaceuticals, LLC | SYMPAZAN (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Neurology | ||||||
| 11/06/2024 | Aucta Pharmaceuticals, Inc. | Motpoly XR (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Central Nervous System | ||||||
| 11/05/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 10/30/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Neurology | ||||||
| 10/23/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $26.41 | General |
| 10/08/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $26.96 | General |
| 10/03/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: Neurology | ||||||
| 09/25/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: Neurology | ||||||
| 09/11/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2024 | Otter Pharmaceuticals, LLC | SYMPAZAN (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Neurology | ||||||
| 09/11/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: Neurology | ||||||
| 09/10/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 09/09/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $23.54 | General |
| 08/29/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Post Approval Study | NEUROPACE, INC. | $18,832 | 54 |
| A LONG-TERM SAFETY STUDY TO ASSESS THE POTENTIAL FOR CHRONIC LIVER INJURY IN PARTICIPANTS TREATED WITH EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION | JAZZ PHARMACEUTICALS INC. | $4,723 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 707 | 1,141 | $538,168 | $130,363 |
| 2022 | 15 | 887 | 1,355 | $531,846 | $151,197 |
| 2021 | 17 | 1,008 | 1,596 | $651,002 | $181,969 |
| 2020 | 13 | 538 | 922 | $354,706 | $86,008 |
Total Patients
3,140
Total Services
5,014
Medicare Billing
$549,537
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 141 | 230 | $66,240 | $27,716 | 41.8% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 49 | 169 | $207,900 | $26,989 | 13.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 323 | $63,470 | $23,641 | 37.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 55 | 57 | $23,606 | $15,716 | 66.6% |
| 95708 | Measurement of brain wave activity (eeg), 12-26 hours | Office | 2023 | 31 | 75 | $30,000 | $8,884 | 29.6% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2023 | 43 | 61 | $37,800 | $6,296 | 16.7% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2023 | 31 | 31 | $6,200 | $4,758 | 76.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 64 | $8,512 | $3,980 | 46.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 25 | $9,338 | $3,409 | 36.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,038 | $2,971 | 42.2% |
| 95723 | Measurement of brain wave activity (eeg), 61-84 hours with health care professional review and report | Office | 2023 | 15 | 15 | $41,625 | $2,847 | 6.8% |
| 95721 | Measurement of brain wave activity (eeg), 37-60 hours with health care professional review and report | Office | 2023 | 15 | 15 | $27,000 | $2,415 | 8.9% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 31 | 59 | $9,440 | $741.50 | 7.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 171 | 260 | $74,880 | $33,377 | 44.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 282 | 389 | $76,439 | $28,225 | 36.9% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 39 | 123 | $154,980 | $20,280 | 13.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 60 | 60 | $26,430 | $18,923 | 71.6% |
| 95708 | Measurement of brain wave activity (eeg), 12-26 hours | Office | 2022 | 30 | 80 | $32,000 | $9,976 | 31.2% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2022 | 23 | 39 | $19,500 | $8,683 | 44.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 31 | 102 | $13,566 | $5,796 | 42.7% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2022 | 30 | 31 | $6,100 | $4,895 | 80.2% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2022 | 33 | 45 | $28,350 | $4,753 | 16.8% |
| 95723 | Measurement of brain wave activity (eeg), 61-84 hours with health care professional review and report | Office | 2022 | 21 | 21 | $58,275 | $4,179 | 7.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 74 | 81 | $11,340 | $3,256 | 28.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $6,210 | $2,476 | 39.9% |
About Dr. Sami Aboumatar, M.D
Dr. Sami Aboumatar, M.D is a Neurology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760445407.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sami Aboumatar, M.D has received a total of $159,184 in payments from pharmaceutical and medical device companies, with $16,508 received in 2024. These payments were reported across 611 transactions from 50 companies. The most common payment nature is "Consulting Fee" ($35,545).
As a Medicare-enrolled provider, Aboumatar has provided services to 3,140 Medicare beneficiaries, totaling 5,014 services with total Medicare billing of $549,537. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Austin, TX
- Active Since 04/11/2006
- Last Updated 11/15/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760445407
Products in Payments
- XCOPRI (Drug) $35,141
- SYMPAZAN (Drug) $22,156
- RNS System (Device) $21,581
- APTIOM (Drug) $20,832
- Fycompa (Drug) $10,939
- Fintepla (Drug) $9,631
- RNS Neurostimulator Kit (Device) $8,302
- Banzel (Drug) $5,587
- EPIDIOLEX (Drug) $5,040
- Cenobamate (Drug) $2,175
- Epidiolex (Drug) $1,935
- VNS Therapy (Device) $1,215
- Briviact (Drug) $1,059
- ACTIVA (Device) $217.50
- UBRELVY (Drug) $195.68
- Aimovig (Biological) $189.72
- VNS Therapy SenTiva Model 1000 Generator (Device) $179.86
- NURTEC ODT (Drug) $126.81
- NUEDEXTA (Drug) $105.31
- Trintellix (Drug) $90.69
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Austin
Dr. Elliot Frohman, Md Phd, MD PHD
Neurology — Payments: $633,909
Neurology $633,909
Dr. David Morledge, M.d, M.D
Neurology — Payments: $180,453
Neurology $180,453
Dr. Subhashie Wijemanne, M.d, M.D
Neurology — Payments: $140,816
Neurology $140,816
Dr. Krishna Pokala, Md, MD
Neurology — Payments: $103,512
Neurology $103,512
Dr. Rajat Gupta, M.d, M.D
Neurology — Payments: $91,931
Neurology $91,931
Dr. Robert Izor, Md, MD
Neurology — Payments: $70,941
Neurology $70,941